, , p.33
, , p.36
,
, Lung cancer survival in Norway, vol.47, pp.275-287, 1997.
Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, PLOS ONE, vol.10, p.121323, 1973. ,
One-year survival improvement in lung cancer in France. Results of the prospective real life studies, Rev Pneumol Clin, vol.72, pp.163-170, 2016. ,
Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients, Lung Cancer, vol.86, pp.14-21, 2014. ,
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, Journal of Thoracic Oncology, vol.11, pp.39-51, 2016. ,
The Future in Diagnosis and Staging of Lung Cancer: Positron Emission Tomography, Respiration, vol.73, pp.267-276, 2006. ,
Small cell lung cancer: patterns of care and their influence on survival -25 years experience of a single Australian oncology unit, Asia Pac J Clin Oncol, vol.7, pp.252-257, 2011. ,
Carboplatin-or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data, Journal of Clinical Oncology, vol.30, pp.1692-1698, 2012. ,
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, ESMO Guidelines Working Group, vol.24, pp.99-105, 2013. ,
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer, New England Journal of Medicine, vol.357, pp.664-672, 2007. ,
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J. Clin. Oncol, vol.17, pp.658-667, 1999. ,
Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients, Lung Cancer, vol.78, pp.112-120, 2012. ,
Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am. J. Clin. Oncol, vol.5, pp.649-655, 1982. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, pp.228-247, 2009. ,
Treatment of small cell lung cancer, Critical Reviews in Oncology/Hematology, vol.52, pp.117-126, 2004. ,
New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases, Journal of Thoracic Disease, vol.9, pp.5101-5111, 2017. ,
Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit, PLoS ONE, vol.9, p.89426, 2014. ,
, Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact, vol.16, pp.282-291, 2015.
Barros-Dios, Small cell lung cancer in never-smokers, European Respiratory Journal, vol.47, pp.947-953, 2016. ,
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between, Small Cell Lung Cancer in SEER-Medicare, vol.122, pp.50-60, 1985. ,
Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study, OncoTargets and Therapy, p.1921, 2016. ,
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis, Clinical and Translational Oncology, vol.15, pp.843-848, 2013. ,
Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ? 3rd line small cell lung cancer: Results from the phase 2 TRINITY study ,